393 related articles for article (PubMed ID: 32031298)
1. Therapeutic potential of PPARγ natural agonists in liver diseases.
Wu L; Guo C; Wu J
J Cell Mol Med; 2020 Mar; 24(5):2736-2748. PubMed ID: 32031298
[TBL] [Abstract][Full Text] [Related]
2. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
[TBL] [Abstract][Full Text] [Related]
3. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review.
Wang L; Waltenberger B; Pferschy-Wenzig EM; Blunder M; Liu X; Malainer C; Blazevic T; Schwaiger S; Rollinger JM; Heiss EH; Schuster D; Kopp B; Bauer R; Stuppner H; Dirsch VM; Atanasov AG
Biochem Pharmacol; 2014 Nov; 92(1):73-89. PubMed ID: 25083916
[TBL] [Abstract][Full Text] [Related]
4. Identification of PPARγ Agonists from Natural Sources Using Different In Silico Approaches.
El-Houri RB; Mortier J; Murgueitio MS; Wolber G; Christensen LP
Planta Med; 2015 Apr; 81(6):488-94. PubMed ID: 25251562
[TBL] [Abstract][Full Text] [Related]
5. A role of peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease.
Skat-Rørdam J; Højland Ipsen D; Lykkesfeldt J; Tveden-Nyborg P
Basic Clin Pharmacol Toxicol; 2019 May; 124(5):528-537. PubMed ID: 30561132
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice.
Kuboki S; Shin T; Huber N; Eismann T; Galloway E; Schuster R; Blanchard J; Zingarelli B; Lentsch AB
Hepatology; 2008 Jan; 47(1):215-24. PubMed ID: 18085707
[TBL] [Abstract][Full Text] [Related]
7. Natural Peroxisome Proliferator-Activated Receptor γ (PPARγ) Activators for Diabetes.
Abdallah HM; El Dine RS; Mohamed GA; Ibrahim SRM; Shehata IA; El-Halawany AM
Altern Ther Health Med; 2020 Jul; 26(S2):28-44. PubMed ID: 31221946
[TBL] [Abstract][Full Text] [Related]
8. Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model.
Nakano Y; Arima T; Tobita Y; Uchiyama M; Shimizu A; Takahashi H
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707656
[TBL] [Abstract][Full Text] [Related]
9. Hepatic Peroxisome Proliferator-Activated Receptor Gamma Signaling Contributes to Alcohol-Induced Hepatic Steatosis and Inflammation in Mice.
Zhang W; Sun Q; Zhong W; Sun X; Zhou Z
Alcohol Clin Exp Res; 2016 May; 40(5):988-99. PubMed ID: 27062444
[TBL] [Abstract][Full Text] [Related]
10. Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice.
Akahori T; Sho M; Hamada K; Suzaki Y; Kuzumoto Y; Nomi T; Nakamura S; Enomoto K; Kanehiro H; Nakajima Y
J Hepatol; 2007 Dec; 47(6):784-92. PubMed ID: 17936399
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice.
Da Silva Morais A; Abarca-Quinones J; Horsmans Y; Stärkel P; Leclercq IA
Int J Mol Med; 2007 Jan; 19(1):105-12. PubMed ID: 17143554
[TBL] [Abstract][Full Text] [Related]
12. Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists.
Deng YL; Xiong XZ; Cheng NS
Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):467-78. PubMed ID: 23060391
[TBL] [Abstract][Full Text] [Related]
13. The role of peroxisome proliferator-activated receptor-γ in breast cancer.
Kotta-Loizou I; Giaginis C; Theocharis S
Anticancer Agents Med Chem; 2012 Nov; 12(9):1025-44. PubMed ID: 22583414
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target.
Mansure JJ; Nassim R; Kassouf W
Cancer Biol Ther; 2009 Apr; 8(7):6-15. PubMed ID: 19417560
[TBL] [Abstract][Full Text] [Related]
15. Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation.
Guasch L; Sala E; Castell-Auví A; Cedó L; Liedl KR; Wolber G; Muehlbacher M; Mulero M; Pinent M; Ardévol A; Valls C; Pujadas G; Garcia-Vallvé S
PLoS One; 2012; 7(11):e50816. PubMed ID: 23226391
[TBL] [Abstract][Full Text] [Related]
16. Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor γ.
de Groot JC; Weidner C; Krausze J; Kawamoto K; Schroeder FC; Sauer S; Büssow K
J Med Chem; 2013 Feb; 56(4):1535-43. PubMed ID: 23286787
[TBL] [Abstract][Full Text] [Related]
17. [PPARgamma agonists for the diseases of gastrointestinal tract and liver].
Shimada T; Hiraishi H
Nihon Rinsho; 2010 Feb; 68(2):312-6. PubMed ID: 20158102
[TBL] [Abstract][Full Text] [Related]
18. Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists.
Tanrikulu Y; Rau O; Schwarz O; Proschak E; Siems K; Müller-Kuhrt L; Schubert-Zsilavecz M; Schneider G
Chembiochem; 2009 Jan; 10(1):75-8. PubMed ID: 19067454
[No Abstract] [Full Text] [Related]
19. Potential of Natural Products in the Inhibition of Adipogenesis through Regulation of PPARγ Expression and/or Its Transcriptional Activity.
Feng S; Reuss L; Wang Y
Molecules; 2016 Sep; 21(10):. PubMed ID: 27669202
[TBL] [Abstract][Full Text] [Related]
20. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
